$TNDM News

Wells Fargo Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $27

Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $17

B of A Securities Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25

Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Benchmark Initiates Coverage On Tandem Diabetes Care with Hold Rating

Tandem Diabetes Care, Inc. 2026 Q1 - Results - Earnings Call Presentation

Truist Securities Reiterates Buy on Tandem Diabetes Care, Lowers Price Target to $31

Barclays Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $55

Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript

Tandem Diabetes Care (NASDAQ:TNDM) Surges 10% After Q1 Beat on Revenue and Earnings

Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.076B Est.

Tandem Diabetes Care Q1 Adj. EPS $(0.30) Beats $(0.45) Estimate, Sales $247.221M Beat $241.125M Estimate.

Tandem Diabetes Care Announces FDA Approval For Insulin Delivery Devices Using Control-IQ+ Technology For Use In Pregnancy-Complicated Type 1 Diabetes Mellitus

Tandem Diabetes Care Announces FDA Approval For Insulin Delivery Devices Using Control-IQ+ Technology For Use In Pregnancy-Complicated Type 1 Diabetes Mellitus

FDA Flags High-Risk Recall For Tandem Diabetes Mobi Pumps

TD Cowen Maintains Buy on Tandem Diabetes Care, Raises Price Target to $28

Goldman Sachs Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25

Assessing Tandem Diabetes Care (TNDM) Valuation After Recent Share Price Weakness

Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026

3 Reasons to Sell TNDM and 1 Stock to Buy Instead